Suppr超能文献

自癌症诊断以来,感知到的大麻风险和益处与大麻使用之间的关联。

The association of perceived cannabis risks and benefits with cannabis use since cancer diagnosis.

机构信息

Division of Health Promotion and Behavioral Science, School of Public Health, San Diego State University, San Diego, CA, USA.

Moores Cancer Center at UC San Diego Health, La Jolla, CA, USA.

出版信息

J Natl Cancer Inst Monogr. 2024 Aug 15;2024(66):244-251. doi: 10.1093/jncimonographs/lgad024.

Abstract

BACKGROUND

Many patients with cancer use cannabis to help alleviate untreated cancer symptoms and side effects.

METHODS

We examined associations of perceived benefits and risks and postdiagnosis cannabis use in a weighted sample of adult cancer survivors through a 1-time survey. Fifteen perceived cannabis use benefits and 19 perceived risks were operationalized as both summary scores and report of any benefits or risks. Survey-weighted logistic regression provided covariate-adjusted odds of postdiagnosis cannabis use for each benefit-risk measure.

RESULTS

Among the weighted population of 3785 survivors (mean [SD] age = 62.2 [13.5] years), one-third used cannabis after diagnosis. Perceiving any benefits increased the odds of postdiagnosis cannabis use more than 500%, and perceiving any risks lowered the odds by 59%. Each SD increase in endorsed benefits doubled the odds of postdiagnosis cannabis use, while each SD increase in endorsed risks reduced the odds by 36%.

CONCLUSION

An accurate understanding of benefits and risks is critical for informed decision making.

摘要

背景

许多癌症患者使用大麻来缓解未经治疗的癌症症状和副作用。

方法

我们通过一次性调查,在加权样本的成年癌症幸存者中检查了感知到的益处和风险与诊断后大麻使用之间的关联。15 种感知到的大麻使用益处和 19 种感知到的风险被定义为综合得分和任何益处或风险的报告。经过调查加权的逻辑回归为每种益处-风险衡量标准提供了诊断后大麻使用的调整后比值比。

结果

在加权的 3785 名幸存者人群中(平均[标准差]年龄=62.2[13.5]岁),有三分之一的人在诊断后使用了大麻。感知到任何益处会使诊断后使用大麻的几率增加 500%以上,而感知到任何风险会使几率降低 59%。每增加一个标准差的认可益处会使诊断后使用大麻的几率增加一倍,而每增加一个标准差的认可风险会使几率降低 36%。

结论

准确了解益处和风险对于做出明智的决策至关重要。

相似文献

5
Cannabis and schizophrenia.大麻与精神分裂症。
Cochrane Database Syst Rev. 2014 Oct 14;2014(10):CD004837. doi: 10.1002/14651858.CD004837.pub3.
6
Cannabis-based medicines for chronic neuropathic pain in adults.用于成人慢性神经性疼痛的大麻类药物。
Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2.
7
Psychosocial interventions for cannabis use disorder.针对大麻使用障碍的心理社会干预措施。
Cochrane Database Syst Rev. 2016 May 5;2016(5):CD005336. doi: 10.1002/14651858.CD005336.pub4.

引用本文的文献

1
Overview of cancer patient perspectives on cannabis use during treatment.癌症患者对治疗期间使用大麻的看法概述。
J Natl Cancer Inst Monogr. 2024 Aug 15;2024(66):199-201. doi: 10.1093/jncimonographs/lgae025.

本文引用的文献

1
Use of Medical Cannabis by Patients With Cancer: Attitudes, Knowledge, and Practice.癌症患者使用医用大麻:态度、知识和实践。
J Pain Symptom Manage. 2023 Sep;66(3):203-211.e1. doi: 10.1016/j.jpainsymman.2023.05.010. Epub 2023 May 25.
2
Assessment of Medical Cannabis and Health-Related Quality of Life.评估医用大麻与健康相关的生活质量。
JAMA Netw Open. 2023 May 1;6(5):e2312522. doi: 10.1001/jamanetworkopen.2023.12522.
8
Tetrahydrocannabinols: potential cannabimimetic agents for cancer therapy.四氢大麻酚:用于癌症治疗的潜在大麻模拟剂。
Cancer Metastasis Rev. 2023 Sep;42(3):823-845. doi: 10.1007/s10555-023-10078-2. Epub 2023 Jan 25.
10
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验